Snape; Michael Frederick

Patent Applications and Registrations

Patent applications and USPTO patent grants for Snape; Michael Frederick.The latest application filed is for "bicyclic compounds and methods for their use in treating autistic disorder and autism".

Company Profile

2.7.9

Snape; Michael Frederick - Surrey GB
Snape; Michael Frederick - Thames Ditton N/A GB
Snape; Michael Frederick - Wonersh Surrey
Snape; Michael Frederick - Winnersh GB
Snape, Michael Frederick - London GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Bicyclic compounds and methods for their use in treating autism Grant 11,197,856 - Glass , et al. December 14, 2	2021-12-14
Bicyclic Compounds and Methods for Their Use in Treating Autistic Disorder and Autism App 20200163961 - Glass; Lawrence Irwin ; et al.	2020-05-28
Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders Grant 10,548,892 - Glass , et al. Fe	2020-02-04
Neuroprotective Bicyclic Compounds and Methods for Their Use in Treating Autism Spectrum Disorders and Neurodevelopmental Disorders App 20180140601 - Glass; Lawrence Irwin ; et al.	2018-05-24
Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders Grant 9,867,823 - Glass , et al. January 16, 2	2018-01-16
Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate Grant 9,708,366 - Glass , et al. July 18, 2	2017-07-18
Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders App 20170020869 - Glass; Lawrence Irwin ; et al.	2017-01-26
Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid Grant 9,212,204 - Glass , et al. December 15, 2	2015-12-15
Treatment Of Autism Spectrum Disorders Using Glycyl-l-2-methylprolyl-l-glumatic Acid App 20150224164 - Glass; Lawrence Irwin ; et al.	2015-08-13
Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid App 20150197543 - Glass; Lawrence Irwin ; et al.	2015-07-16
Treatment Of Autism Spectrum Disorders Using Glycyl-l-2-methylprolyl-l-glutamic Acid App 20140147491 - Glass; Larry ; et al.	2014-05-29
2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission Grant 6,828,318 - Snape , et al. December 7, 2	2004-12-07
2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission App 20030207881 - Snape, Michael Frederick ; et al.	2003-11-06
1-(Adamantyl) amidines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission App 20030130354 - Gillespie, Roger John ; et al.	2003-07-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.